130 related articles for article (PubMed ID: 18604721)
41. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
[TBL] [Abstract][Full Text] [Related]
42. Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma.
Chung KM; Chang ST; Huang WT; Lu CL; Wu HC; Hwang WS; Chang KY; Chuang SS
J Formos Med Assoc; 2013 Jul; 112(7):382-9. PubMed ID: 23927977
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathologic evaluation of subgroups of diffuse large B cell lymphoma by immunohistochemistry.
Naz E; Mirza T; Danish F
Asian Pac J Cancer Prev; 2011; 12(12):3335-9. PubMed ID: 22471476
[TBL] [Abstract][Full Text] [Related]
44. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
45. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
Li M; Liu CL; Wang XY; Xue XM; Gao ZF
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229
[TBL] [Abstract][Full Text] [Related]
46. [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
Liang X; Wang J; Bai W; Sun R
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):559-64. PubMed ID: 26705179
[TBL] [Abstract][Full Text] [Related]
47. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
48. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
49. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype.
Heyning FH; Hogendoorn PC; Kramer MH; Holland CT; Dreef E; Jansen PM
J Clin Pathol; 2009 Sep; 62(9):820-4. PubMed ID: 19734480
[TBL] [Abstract][Full Text] [Related]
50. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
51. The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas.
Rayman N; Lam KH; van der Holt B; Koss C; van Leeuwen J; Budel LM; Mulder AH; Sonneveld P; Delwel R
Eur J Haematol; 2011 Jun; 86(6):466-76. PubMed ID: 21457344
[TBL] [Abstract][Full Text] [Related]
52. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
[TBL] [Abstract][Full Text] [Related]
53. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
54. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
55. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
56. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
[TBL] [Abstract][Full Text] [Related]
57. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Gutiérrez-García G; Cardesa-Salzmann T; Climent F; González-Barca E; Mercadal S; Mate JL; Sancho JM; Arenillas L; Serrano S; Escoda L; Martínez S; Valera A; Martínez A; Jares P; Pinyol M; García-Herrera A; Martínez-Trillos A; Giné E; Villamor N; Campo E; Colomo L; López-Guillermo A;
Blood; 2011 May; 117(18):4836-43. PubMed ID: 21441466
[TBL] [Abstract][Full Text] [Related]
58. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.
Benesova K; Forsterova K; Votavova H; Campr V; Stritesky J; Velenska Z; Prochazka B; Pytlik R; Trneny M
Neoplasma; 2013; 60(1):68-73. PubMed ID: 23067219
[TBL] [Abstract][Full Text] [Related]
59. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
[TBL] [Abstract][Full Text] [Related]
60. Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas.
Mitchell KA; Finn WG; Owens SR
Leuk Lymphoma; 2008 Sep; 49(9):1717-23. PubMed ID: 18798105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]